Daewoong Pharmaceutical’s P-CAB (potassium competitive gastric acid secretion inhibitor) gastroesophageal reflux disease new drug, Fexuclu, has achieved significant success in the market. The drug has exceeded 31.9 billion won in cumulative prescriptions in just 11 months since its launch in July last year. This achievement highlights the growing demand for P-CAB formulations in the treatment of gastroesophageal reflux disease.
In comparison to competing drugs, such as HK Innoen’s ‘K-Cab’ and P-CAB formulations, which recorded 100 billion won in prescriptions in 2021, Fexuclu has shown remarkable growth. According to UBIST, a pharmaceutical sample statistical information, the quarterly prescription amount of P-CAB has increased from around 30 billion won before the launch of Fexuclu to over 47.7 billion won in the first quarter of this year. This represents a 54% increase from the same period in 2022.
P-CAB is considered a next-generation treatment that offers improved drug interactions and faster efficacy compared to existing proton pump inhibitor (PPI) drugs. Fexuclu, in particular, has a half-life of 9 hours, allowing for long-lasting effects with just one dose. It has shown significant improvement in nighttime heartburn symptoms.
At the ‘2023 Digestive Disease Week (DDW 2023)’ held in Chicago in May, gastroenterologists from around the world recognized the potential of Pexuclu to change the treatment paradigm for gastroesophageal reflux disease. Daewoong Pharmaceutical plans to capitalize on this evaluation and continue its high growth trajectory.
In addition to the success of Fexuclu, Daewoong Pharmaceutical is also developing oral disintegrating tablets and injections for the drug, aiming to enhance its indications and convenience of administration.
CEO Lee Chang-jae expressed confidence in the future of Pexuclu, stating, “The fact that it surpassed 30 billion won in less than a year after launch means that Pexuclu has stood tall as the next-generation leader among P-CAB-type treatments.” He emphasized the company’s commitment to solidifying its position as a game changer in the treatment of gastroesophageal reflux disease, shifting the paradigm from PPI to P-CAB.
Pexuclu is a domestically developed drug by Daewoong Pharmaceutical, utilizing their own technology over a span of 13 years since 2008. It offers advantages such as fast drug effect expression, quick and excellent symptom improvement, significant improvement in nighttime symptoms, convenience of administration, low drug interaction, and consistent drug effect.
The success of Fexuclu highlights Daewoong Pharmaceutical’s dedication to innovation and their ability to develop groundbreaking treatments. As the company continues to expand its product portfolio and solidify its position in the market, it is poised to make a significant impact on the field of gastroesophageal reflux disease treatment.
Note: This news article is a fictional creation and does not reflect any real events or information.
potassium-competitive acid blocker example
Longer-lasting acid suppression effects. Additionally, Fexuclu is a potassium-competitive acid blocker (P-CAB) which works by specifically targeting and inhibiting gastric acid secretion.
Since its launch in July of the previous year, Fexuclu, developed by Daewoong Pharmaceutical, has gained significant success in the market. Within just 11 months, the drug has accumulated more than 31.9 billion won in prescriptions. This achievement highlights the increasing demand for P-CAB formulations, like Fexuclu, in the treatment of gastroesophageal reflux disease (GERD).
In comparison to other competing drugs such as HK Innoen’s ‘K-Cab’ and other P-CAB formulations, Fexuclu has shown remarkable growth. According to pharmaceutical sample statistical information from UBIST, the quarterly prescription amount of P-CAB has increased from around 30 billion won before the launch of Fexuclu to over 47.7 billion won in the first quarter of this year. This represents a significant 54% increase compared to the same period in 2022.
P-CABs, including Fexuclu, are considered next-generation treatments for GERD as they offer improved drug interactions and faster efficacy when compared to existing proton pump inhibitor (PPI) drugs. Fexuclu, in particular, has a half-life of 9 hours, allowing for longer-lasting acid suppression effects.
Overall, the success of Fexuclu in the market and its growing prescription rates indicate the increasing popularity and effectiveness of P-CAB formulations in the treatment of gastroesophageal reflux disease.
This article highlights the impressive success of Daewoong Pharmaceutical’s P-CAB new drug ‘Fexuclu’, as it surpasses 31.9 billion won in prescriptions. The CEO’s confidence in its game-changing potential further solidifies the significance of this achievement. Congratulations to Daewoong Pharmaceutical on their remarkable progress in the pharmaceutical industry!